Rendering of Seagen's Everett, WA, biomanufacturing facility (Graphic: Business Wire)
March 4, 2024 11:34 AM ESTUpdated March 5, 01:29 PM
Manufacturing

Pfiz­er to 'wind down con­struc­tion' of Seagen's $350M man­u­fac­tur­ing site

Anna Brown

News Reporter

Pfiz­er is set to stop con­struc­tion of a man­u­fac­tur­ing fa­cil­i­ty start­ed by Seagen in Wash­ing­ton state, with af­fect­ed em­ploy­ees pos­si­bly mov­ing to oth­er fa­cil­i­ties, a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times